Safety and Immunogenicity of NVX-CoV2705
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Novavax.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Prevention
Enrollment
676actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-09 | actual | When the study began enrolling |
| Primary completion | 2026-01-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-11 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- COVID-19
- SARS-CoV-2 Infection
Intervention
- Biological: NVX-CoV2705 — also filed as Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M
Primary outcome
what the primary-completion date above is the date OFPseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMFR
measured Day 28
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed